MB

Merlin Biomed

North America, New York, United States, New York

Description

Network Solutions - Original domain name registration and reservation services with variety of internet-related business offerings.

Investor Profile

Merlin Biomed has made 18 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series Unknown (33%)
  • Series D (28%)
  • Series C (17%)
  • Series E (11%)
  • Series B (6%)
  • Post Ipo Equity (6%)

Country Focus

  • United States (83%)
  • United Kingdom (11%)
  • Canada (6%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Biopharma
  • Medical
  • Oncology
  • Information Technology
  • Medical Device
  • Developer Tools
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Merlin Biomed frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 4
NB
North America, Maryland, United States, Gaithersburg
Co-Investments: 2
Sprout Group
North America, New York, United States, New York
Co-Investments: 2
MPM Capital
North America, Massachusetts, United States, Boston
Co-Investments: 4
Versant Ventures
North America, California, United States, Menlo Park
Co-Investments: 3
Montreux Equity Partners
North America, California, United States, San Francisco
Co-Investments: 2
Scottish Widows Investment Partnership
Europe, Edinburgh, City of, United Kingdom, Edinburgh
Co-Investments: 2
VantagePoint Capital Partners
North America, California, United States, San Bruno
Co-Investments: 3
PV
Europe, England, United Kingdom, London
Co-Investments: 2
JL
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2

What are some of recent deals done by Merlin Biomed?

CymaBay Therapeutics

Hayward, California, United States

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

BiopharmaBiotechnologyPharmaceutical
Series ENov 5, 2009
Amount Raised: $8,600,000
Gemin X Pharmaceuticals

Montréal, Quebec, Canada

Gemin X Pharmaceuticals develops and commercializes targeted cancer therapeutics to improve the lives of patients.

BiotechnologyPharmaceuticalTherapeutics
Series CJul 3, 2008
Amount Raised: $38,000,000
CymaBay Therapeutics

Hayward, California, United States

CymaBay Therapeutics is focused on the development and commercialization of proprietary new medicines for critical human diseases.

BiopharmaBiotechnologyPharmaceutical
Series DApr 19, 2007
Amount Raised: $32,000,000
Calypso Medical

Seattle, Washington, United States

Calypso Medical develops tumor localization systems designed to accurately and objectively track the location of tumors in human bodies.

Health CareMedicalMedical Device
Series DJan 8, 2007
Amount Raised: $42,200,000
EUSA Pharma

Hemel Hempstead, Hertford, United Kingdom

EUSA Pharma is a pharmaceutical company developing and licensing late-stage oncology, pain control, and critical care products.

BiotechnologyHealth CareMedicalOncologyPharmaceutical
Series UnknownNov 7, 2006
Amount Raised: $18,600,000
RenaMed Biologics

Westborough, Massachusetts, United States

RenaMed Biologics engages in the development of therapies for the treatment of diseases associated with compromised kidney function.

BiotechnologyHealth CareMedical
Series UnknownSep 7, 2006
Amount Raised: $40,000,000
Genelabs Technologies

Redwood City, California, United States

Genelabs Technologies is a biopharmaceutical company engaged in the R&D of therapeutics for the treatment of infectious diseases.

BiopharmaBiotechnologyHealth CareTherapeutics
Series UnknownJun 27, 2006
Amount Raised: $8,300,000
ARYx Therapeutics

Fremont, California, United States

ARYx is a pharmaceutical company focused on retrometabolic drug designing and improving the safety of oral therapies for chronic diseases.

BiotechnologyPharmaceuticalTherapeutics
Series EFeb 10, 2006
Amount Raised: $30,400,000
Affymax

Cupertino, California, United States

Affymax is a biopharmaceutical company.

BiopharmaBiotechnologyHealth Care
Series DJul 18, 2005
Amount Raised: $60,000,000
FibroGen

San Francisco, California, United States

FibroGen uses its expertise in CTGF and HIF biology to discover, develop, and commercialize novel therapeutics.

BiopharmaBiotechnologyHealth CareTherapeutics
Series UnknownFeb 17, 2005
Amount Raised: $100,000,000